Anthony P. Bihl III - 10 Apr 2023 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Interim CEO, Director
Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
10 Apr 2023
Net transactions value
$0
Form type
4
Filing time
12 Apr 2023, 20:26:45 UTC
Previous filing
10 Apr 2023
Next filing
24 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Award $0 +76,000 $0.000000 76,000 10 Apr 2023 Class A Common Stock 76,000 Direct F1, F2
transaction BVS Stock Option (Right to Buy) Award $0 +198,000 $0.000000 198,000 10 Apr 2023 Class A Common Stock 198,000 $1.16 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs and options, as applicable, vest on April 10, 2024.